Qutenza (Topical Capsaicin 8%) for Painful Arteriovenous Fistulae
The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Arteriovenous Fistulae in Patients With End Stage Renal Failure
Sponsor: NHS Greater Glasgow and Clyde
A observational or N/A phase clinical study on Arteriovenous Fistulae and Neuropathic Pain, this trial is ongoing. The trial is conducted by NHS Greater Glasgow and Clyde and has accumulated 7 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Dec 2018 — Jan 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Dec 2018 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NHS Greater Glasgow and Clyde
For direct contact, visit the study record on ClinicalTrials.gov .